We collected information on all the groups who have made a submission to the recent EU public consultation on regulation of blood, tissues and cells, and compared this to the list of groups who made a submission to the public consultations on regulation of advanced therapies (medicines made from cells, tissues or genes). It could have been expected to find the same groups contributing to both pieces of legislation because these two pieces of legislation apply consecutively when developing a medicine based on genes, cells or tissues. However, this proved not to be the case, even over time. This fragmented landscape should be taken into account by any policy or regulatory strategy to support the development of those medicines for the benefit of patients.
Help and support
Help and support
- FAQ's
- Glosario